@article{e7f15bd877214ca1a3f77f37af2e7a3a,
title = "Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications",
abstract = "Purpose of Review: Along with population aging, the incidence of both heart failure (HF) and cancer is increasing. However, little is known about new-onset cancer in HF patients. This review aims at showing recent discoveries concerning this subset of patients. Recent Findings: Not only cancer and HF share similar risk factors but also HF itself can stimulate cancer development. Some cytokines produced by the failing heart induce mild inflammation promoting carcinogenesis, as it has been recently suggested by an experimental model of HF in mice. Summary: The incidence of new-onset cancer is higher in HF patients compared to the general population, and it significantly worsens their prognosis. Moreover, the management of HF patients developing new-onset cancer is challenging, especially due to the limited therapeutic options for patients affected by both cancer and HF and the higher risk of cardiotoxicity from anticancer drugs.",
keywords = "Aging, Cancer, Cardio-oncology, Heart failure, Pathophysiology, Risk factors",
author = "Alessandra Cuomo and Flora Pirozzi and Umberto Attanasio and Riccardo Franco and Francesco Elia and {De Rosa}, Eliana and Michele Russo and Alessandra Ghigo and Pietro Ameri and Tocchetti, {Carlo Gabriele} and Valentina Mercurio",
note = "Funding Information: Alessandra Cuomo, Umberto Attanasio, Riccardo Franco, Francesco Elia, Eliana De Rosa, Michele Russo, and Flora Pirozzi declare no conflict of interest. Valentina Mercurio has received research funding from SIC/MSD. Alessandra Ghigo is a shareholder and board member of Kither Biotech, a spin-off company focused on the development of PI3K inhibitors for airway disease. Pietro Ameri is supported by an investigator-initiated grant from Boehringer Ingelheim; has received speaker{\textquoteright}s honoraria from Novartis, Servier, Daiichi-Sankyo, Pfizer, Boehringer Ingelheim, AstraZeneca, and Merck Sharp & Dohme; and has received compensation for service on advisory boards from Novartis, Daiichi-Sankyo, Bayer, Janssen, and GlaxoSmithKline. Carlo G. Tocchetti has received compensation from Alere for service as a consultant and is listed as an inventor on and receives royalties for Canadian Patent No. 2,613,477 (entitled Thiol-Sensitive Positive Inotropes), issued 3 December 2013, owned by Johns Hopkins University (JHU Ref.: C04755-P04755-05). Publisher Copyright: {\textcopyright} 2020, The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2021",
month = jan,
doi = "10.1007/s11912-020-00990-z",
language = "English",
volume = "23",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "1",
}